United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) CEO Martine Rothblatt sold 9,500 shares of the business's stock in a transaction on Monday, October 19th. The stock was sold at an average price of $543.32, for a total transaction of $5,161,540.00. Following the completion of the sale, the chief executive officer directly owned 324,443 shares in the company, valued at approximately $176,276,370.76. This represents a 2.84% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.
United Therapeutics Stock Up 2.0%
NASDAQ UTHR opened at $553.88 on Wednesday. The company has a market capitalization of $23.76 billion, a price-to-earnings ratio of 19.82, a PEG ratio of 3.89 and a beta of 0.49. United Therapeutics Corporation has a twelve month low of $409.07 and a twelve month high of $609.35. The stock has a fifty day simple moving average of $514.68 and a 200 day simple moving average of $539.60.
United Therapeutics (NASDAQ:UTHR - Get Free Report) last announced its earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.86 by $0.41. The business had revenue of $783.30 million during the quarter, compared to analyst estimates of $804.65 million. United Therapeutics had a return on equity of 20.18% and a net margin of 41.56%. United Therapeutics's revenue for the quarter was down 1.9% compared to the same quarter last year. During the same period last year, the company earned $6.41 EPS. Research analysts expect that United Therapeutics Corporation will post 26.40 earnings per share for the current fiscal year.
More United Therapeutics News
Here are the key news stories impacting United Therapeutics this week:
- Positive Sentiment: Analyst optimism supports the stock. Leerink Partners raised its price target to $725 from $685 while maintaining an “outperform” rating. The broader analyst consensus is a “Moderate Buy,” with an average target of approximately $650. Recent coverage also highlights United Therapeutics as a potentially underappreciated, highly profitable biotechnology company. Analysts Are Bullish on Top Healthcare Stocks United Therapeutics Profit Machine
- Positive Sentiment: FDA clearance advances the SUMMIT trial. The FDA authorized United Therapeutics to proceed with a clinical study of treprostinil inhalation powder, or SMI, in patients with pulmonary hypertension associated with COPD. The trial could expand the company’s addressable market beyond its established pulmonary arterial hypertension business. FDA Clears SUMMIT Study
- Positive Sentiment: Organ-manufacturing capacity is expanding. United Therapeutics opened its third designated pathogen-free xenograft production facility in Houston, strengthening its ability to develop and manufacture genetically modified organs for transplantation. The investment reinforces the company’s longer-term organ-manufacturing strategy. Third Xenograft Production Facility
- Neutral Sentiment: Insider selling adds a modest cautionary signal. CEO Martine Rothblatt sold 9,500 shares in each of two reported transactions, while other executives also sold shares under trading plans. Rothblatt still retains a substantial stake, so the transactions may reflect scheduled diversification rather than a change in business outlook.
Institutional Investors Weigh In On United Therapeutics
A number of hedge funds have recently added to or reduced their stakes in UTHR. Robeco Institutional Asset Management B.V. boosted its holdings in shares of United Therapeutics by 18.8% during the 3rd quarter. Robeco Institutional Asset Management B.V. now owns 146,163 shares of the biotechnology company's stock worth $79,204,000 after buying an additional 23,107 shares in the last quarter. MBM Wealth Consultants LLC increased its stake in shares of United Therapeutics by 6.7% in the 3rd quarter. MBM Wealth Consultants LLC now owns 2,484 shares of the biotechnology company's stock valued at $1,346,000 after acquiring an additional 157 shares in the last quarter. Prime Capital Investment Advisors LLC increased its stake in shares of United Therapeutics by 4.5% in the 3rd quarter. Prime Capital Investment Advisors LLC now owns 1,093 shares of the biotechnology company's stock valued at $592,000 after acquiring an additional 47 shares in the last quarter. Focused Alpha LLC acquired a new position in shares of United Therapeutics during the 3rd quarter valued at $538,000. Finally, Sumitomo Mitsui DS Asset Management Company Ltd lifted its position in shares of United Therapeutics by 0.6% during the 3rd quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 4,775 shares of the biotechnology company's stock valued at $2,588,000 after acquiring an additional 29 shares during the period. 94.08% of the stock is currently owned by institutional investors.
Analysts Set New Price Targets
UTHR has been the subject of several recent research reports. Royal Bank Of Canada increased their price target on United Therapeutics from $677.00 to $708.00 and gave the company an "outperform" rating in a research note on Thursday, October 8th. Raymond James Financial reaffirmed an "outperform" rating and issued a $717.00 price objective on shares of United Therapeutics in a research note on Tuesday. Morgan Stanley upped their target price on United Therapeutics from $515.00 to $566.00 and gave the company an "equal weight" rating in a report on Wednesday, October 7th. JPMorgan Chase & Co. raised their price target on shares of United Therapeutics from $685.00 to $687.00 and gave the stock an "overweight" rating in a report on Thursday, July 23rd. Finally, Bank of America lowered their price target on shares of United Therapeutics from $620.00 to $613.00 and set a "neutral" rating for the company in a report on Friday, July 10th. Twelve investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $651.21.
View Our Latest Analysis on United Therapeutics
United Therapeutics Company Profile
(
Get Free Report)
United Therapeutics Corporation is a biotechnology company focused on developing and commercializing therapies for patients with life-threatening conditions, particularly pulmonary arterial hypertension (PAH). The company's portfolio includes Tyvaso and Tyvaso DPI, inhaled formulations of treprostinil; Remodulin, an injectable treprostinil product; and Orenitram, an oral treprostinil therapy. These treatments are designed to improve exercise ability and delay disease progression in people with PAH.
The company also markets Unituxin, an antibody therapy used as part of treatment for high-risk neuroblastoma, a type of childhood cancer.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
